1. Home
  2. RNXT vs FGEN Comparison

RNXT vs FGEN Comparison

Compare RNXT & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNXT
  • FGEN
  • Stock Information
  • Founded
  • RNXT 2012
  • FGEN 1993
  • Country
  • RNXT United States
  • FGEN United States
  • Employees
  • RNXT N/A
  • FGEN N/A
  • Industry
  • RNXT Biotechnology: Pharmaceutical Preparations
  • FGEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • RNXT Health Care
  • FGEN Health Care
  • Exchange
  • RNXT Nasdaq
  • FGEN Nasdaq
  • Market Cap
  • RNXT 31.6M
  • FGEN 34.5M
  • IPO Year
  • RNXT 2021
  • FGEN 2014
  • Fundamental
  • Price
  • RNXT $1.15
  • FGEN $0.50
  • Analyst Decision
  • RNXT Strong Buy
  • FGEN
  • Analyst Count
  • RNXT 2
  • FGEN 0
  • Target Price
  • RNXT $6.50
  • FGEN N/A
  • AVG Volume (30 Days)
  • RNXT 112.1K
  • FGEN 877.7K
  • Earning Date
  • RNXT 03-31-2025
  • FGEN 02-24-2025
  • Dividend Yield
  • RNXT N/A
  • FGEN N/A
  • EPS Growth
  • RNXT N/A
  • FGEN N/A
  • EPS
  • RNXT N/A
  • FGEN N/A
  • Revenue
  • RNXT N/A
  • FGEN $180,015,000.00
  • Revenue This Year
  • RNXT N/A
  • FGEN $21.91
  • Revenue Next Year
  • RNXT N/A
  • FGEN N/A
  • P/E Ratio
  • RNXT N/A
  • FGEN N/A
  • Revenue Growth
  • RNXT N/A
  • FGEN 16.15
  • 52 Week Low
  • RNXT $0.77
  • FGEN $0.18
  • 52 Week High
  • RNXT $1.86
  • FGEN $2.93
  • Technical
  • Relative Strength Index (RSI)
  • RNXT 58.08
  • FGEN 49.50
  • Support Level
  • RNXT $1.32
  • FGEN $0.46
  • Resistance Level
  • RNXT $1.40
  • FGEN $0.51
  • Average True Range (ATR)
  • RNXT 0.11
  • FGEN 0.05
  • MACD
  • RNXT 0.00
  • FGEN -0.01
  • Stochastic Oscillator
  • RNXT 39.47
  • FGEN 31.25

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Share on Social Networks: